EBS Emergent BioSolutions Inc.companySEC Filings & Insider Trading Activity 2026
Latest Emergent BioSolutions Inc. (EBS) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on February 27, 2026, a 10-Q quarterly report filed on May 1, 2026, an 8-K current report filed on August 5, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Emergent BioSolutions Inc. (EBS) (SEC CIK 1367644), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Emergent BioSolutions Inc.
Ask AI about EBS filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting EBS positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on EBS.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Emergent BioSolutions Inc. (EBS) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.0B | $1.0B | $742.9M |
| Operating Income | - | -$108.7M | $100.1M |
| Net Income | - | -$190.6M | $52.6M |
| Op. Margin | - | -10.4% | 13.5% |
| Net Margin | - | -18.3% | 7.1% |
| Balance Sheet | |||
| Total Assets | $1.8B | $1.4B | $1.3B |
| Equity | $649.3M | $482.8M | $522.6M |
| ROE | - | -39.5% | 10.1% |
| Per Share | |||
| EPS | - | $-3.60 | $0.93 |
| Cash Flow | |||
| Operating CF | - | $58.7M | $170.6M |
| CapEx | $51.6M | $22.9M | $13.8M |
Source: XBRL financial data from Emergent BioSolutions Inc. (EBS) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Aug 5, 2026 | - | - | - |
8-K | Jun 29, 2026 | - | - | - |
10-Q | May 1, 2026 | Mar 31, 2026 | - | |
8-K | Apr 30, 2026 | - | - | - |
8-K | Apr 30, 2026 | - | - | - |
8-K | Apr 17, 2026 | - | - | - |
8-K | Mar 3, 2026 | - | Analysis | - |
10-K | Feb 27, 2026 | Dec 31, 2025 | - | |
8-K | Feb 26, 2026 | - | Analysis | - |
8-K | Jan 14, 2026 | - | - | |
8-K | Jan 12, 2026 | - | - | |
8-K | Dec 12, 2025 | - | - | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | - | |
10-Q | May 8, 2025 | Mar 31, 2025 | - | |
10-K | Mar 4, 2025 | Dec 31, 2024 | - | |
SC 13G | Nov 13, 2024 | - | - | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | - | |
10-Q | May 2, 2024 | Mar 31, 2024 | - | |
10-K | Mar 8, 2024 | Dec 31, 2023 | - | |
SC 13G | Feb 9, 2024 | - | - | |
10-Q | Dec 11, 2023 | Sep 30, 2023 | - | |
SC 13G | Sep 7, 2023 | - | - | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate EBS share value held by 13F filers tracked by SignalX, by quarter.
- AQR Capital Management+511.6K (+107%)
- Dimensional Fund Advisors+504.6K (+22%)
- Prudential Financial+358.9K (+399%)
- Two Sigma Investments+318.6K (+123%)
- Millennium Management+294.3K (+124%)
- Morgan Stanley413.2K (-36%)
- Citadel Advisors LLC271.0K (-68%)
- Truist Financial145.4K (-66%)
- Wells Fargo & Co39.3K (-57%)
- BNY Mellon29.5K (-12%)
- Franklin Resources+161.9K
- Fifth Third Bancorp+204
- Vanguard Group Inc−3.55M
- Invesco Ltd−206.0K
- JPMorgan Chase & Co−21.4K
- Ameriprise Financial−11.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest EBS SEC filings in 2026?
Emergent BioSolutions Inc. (EBS) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on May 1, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did EBS file its most recent 10-K annual report?
Emergent BioSolutions Inc. (EBS) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view EBS 10-Q quarterly reports?
Emergent BioSolutions Inc. (EBS)'s most recent 10-Q quarterly report was filed on May 1, 2026. SignalX displays every EBS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has EBS filed recently?
Emergent BioSolutions Inc. (EBS)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find EBS insider trading activity (Form 4)?
SignalX aggregates every EBS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does EBS file with the SEC?
Emergent BioSolutions Inc. (EBS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new EBS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Emergent BioSolutions Inc. (EBS).
What is EBS's SEC CIK number?
Emergent BioSolutions Inc. (EBS)'s SEC CIK (Central Index Key) number is 1367644. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1367644 to look up all EBS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find EBS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Emergent BioSolutions Inc. (EBS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Emergent BioSolutions Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 67+ filings.